Letters |

Radiation Exposure During Intra-arterial Chemotherapy for Retinoblastoma

Y. Pierre Gobin, MD; Leonard M. Rosenstein, PhD; Brian P. Marr, MD; Scott E. Brodie, MD, PhD; David H. Abramson, MD
Arch Ophthalmol. 2012;130(3):403-405. doi:10.1001/archopthalmol.2011.2717.
Text Size: A A A
Published online


Since our successful introduction of superselective intra-arterial chemotherapy (IAC) for retinoblastoma,1,2 we have been careful to use techniques that limit radiation exposure to the young children who receive treatment. The IAC can be performed with short fluoroscopy time and little or no digital subtraction angiography, so it can be done with significantly lower radiation doses than other procedures in interventional neuroradiology. A recent article by Vijayakrishnan et al,3 however, reported strikingly high doses of radiation during IAC for retinoblastoma. These doses are not only higher than those we have recorded but are even higher than the doses previously reported for performing complex interventional neuroradiology procedures (such as embolization of aneurysms and arteriovenous malformations), which require long fluoroscopy time and multiple digital subtraction angiograms.4,5 For example, in the report by Theodorakou and Horrocks4 on 30 patients undergoing interventional neuroradiology procedures, the right eye (on the side of the lateral fluoroscopy tube) received a mean dose of 60 mGy (to convert to rad, multiply by 0.10), almost 3 times less than in the article by Vijayakrishnan and colleagues.


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





March 1, 2012
Carol L. Shields, MD; Rajakrishnan Vijayakrishnan, MD, PhD; Aparna Ramasubramanian, MD; Jacqueline Emrich, PhD; Pascal Jabbour, MD; Jerry A. Shields, MD
Arch Ophthalmol. 2012;130(3):403-405. doi:10.1001/archopthalmol.2012.173.
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.